Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW
Vaccine. 2006 24 (17): 3686-94

PMID: 16430997 · DOI:10.1016/j.vaccine.2005.03.029

The possible reemergence of smallpox through bioterrorism requires the preparation of adequate stockpiles of vaccine. Dryvax, the only US-licensed vaccinia virus smallpox vaccine, has an unacceptable safety profile in the pre-event setting. LC16m8 is a Japanese-licensed attenuated vaccinia virus strain that has been safely used in over 50,000 persons. Until now, efficacy of this vaccine was unproven. Using two animal models, we show that LC16m8 and Dryvax elicit comparable humoral immune responses after a single vaccination and equivalently protect against lethal poxvirus disease. Thus, LC16m8 shows promise as a safe and effective smallpox vaccine with the potential for replacing Dryvax.

MeSH Terms (11)

Animals Antibodies, Viral Cell Line Female Mice Orthopoxvirus Poxviridae Infections Rabbits Smallpox Vaccine Vaccination Vaccines, Attenuated

Connections (1)

This publication is referenced by other Labnodes entities:

Links